How is the progress of the world's first new drug for schizophrenia approved in the US and in the Chinese market
嬲乜黄
发表于 2024-9-27 20:43:45
1304
0
0
On September 26th local time, the US Food and Drug Administration (FDA) announced the approval of BMS's schizophrenia drug Cobenfy (KarXT, xanomiline and trospium chloride) for the treatment of adult schizophrenia patients.
This is the first approved new mechanism therapy for schizophrenia in decades, targeting cholinergic receptors instead of dopamine receptors, which have long been the standard treatment.
The epidemiological survey of the World Health Organization shows that there are approximately 24 million schizophrenia patients worldwide in 2022. According to Expert Market Research, the global market size for schizophrenia drugs is estimated to grow from $8.18 billion in 2023 to $12.97 billion in 2032, with a compound annual growth rate of 5.26%.
On January 29th of this year, the well-known pharmaceutical website FINECE Pharma released the top 10 most anticipated drugs for 2024, and Cobenfy was listed as the first of the top 10 most anticipated drugs for 2024, with an expected sales revenue of $2.8 billion in 2028.
KarXT is a drug composed of xanomeline (an M1/M4 receptor agonist) and trospium (a non selective muscarinic antagonist), originally developed by Karuna Therapeutics. At the end of 2023, BMS spent $14 billion to acquire Karuna, obtaining this drug and other pipelines. The collaboration between Zaiding Pharmaceutical (09688. HK) and Karuna originated in 2021. At present, Zaiding Pharmaceutical owns the development, production, and commercialization rights of KarXT in Greater China, including mainland China, Hong Kong, Macau, and Taiwan.
Public data shows that there are over 8 million patients with schizophrenia in China. KarXT has been approved in the United States, bringing hope to Chinese patients.
According to NextPharma, the global new drug database of the Medical Magic Cube, there are currently only 16 new drugs under development for schizophrenia in China that have entered clinical trials, and most of them are still dopamine receptor and 5-HT receptor targeted drugs. KarXT is one of the two drugs that have progressed to Phase III clinical stage and is expected to become the next approved new drug for schizophrenia in China. Another drug entering phase III clinical stage is the Gly-T1 inhibitor Iclepertin, developed by Boehringer Ingelheim.
Zaiding Pharmaceutical stated that in August 2024, KarXT's registered study UNITE-1 for schizophrenia had completed the enrollment of all mainland Chinese patients. It is expected to obtain key research data from 2024 to the first half of 2025 and submit a new drug application for KarXT for schizophrenia in mainland China.
In July of this year, Zaiding Pharmaceutical also joined the global Phase III ADEPT-2 study in Greater China to evaluate the safety and efficacy of KarXT in the treatment of Alzheimer's disease related psychiatric disorders.
Affected by the positive news of KarXT's approval for listing in the United States, Zaiding Pharmaceutical rose 10.96% to close at HKD 18.02 per share on September 27th, with a total market value of HKD 17.9 billion.
LogoMoney.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表LogoMoney.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表LogoMoney.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Coca Cola achieved a revenue of $11.854 billion in the third quarter and will continue to invest in the Chinese market
- Ford: China market contributes over $600 million in pre tax profit
- Xu Min, Chairman of Procter&Gamble Greater China: Full of long-term confidence and strategic determination in the Chinese market
- CEO of Johnson Controls Asia Pacific, Lang Zhiwen: Localization is not copying blindly, it needs to meet the actual needs of the Chinese market
- Top 20 US stock transactions: Tesla rises nearly 4%, news reports say Tesla is preparing for Cybertruck electric pickup to enter the Chinese market
- Intel China Chairman Wang Rui: Accelerating the Development of New Quality Productivity and Deepening the Layout of the Chinese Market
- Dialogue with Global Construction Machinery Giant Caterpillar: Pay Attention to the Upgrade Demand of Equipment Trade in in the Chinese Market
- Rare Report Responds to Doubts of 'Apple Tax'! Deliberately avoiding differential treatment of the Chinese market? Apple: Should not publicly comment
- Will Nvidia cut off supply to the Chinese market after being investigated for anti-monopoly? Official Refutation: Rumors are not true
- BeiGene ADC's new cancer drug BG-C137 has been clinically approved for the first time in China
-
美国总统特朗普表示,美国不能在欧盟销售汽车很“不好”,不寻求达成协议,6月1日起对欧盟征收50%关税。如果他们在这里建工厂,可以讨论延期。特朗普表示,对不在美国生产的手机制造商征收25%的关税。特朗普警告 ...
- zerken
- 2 小时前
- 支持
- 反对
- 收藏
-
中汽协:4月中国品牌乘用车共销售157.1万辆,同比增长23.5% 据中国汽车工业协会统计分析,2025年4月,中国品牌乘用车共销售157.1万辆,环比下降3.5%,同比增长23.5%,占乘用车销售总量的70.7%,销量占有率比 ...
- ELUNSHI
- 4 小时前
- 支持
- 反对
- 收藏
-
美东时间周五,美国总统特朗普威胁苹果称,如果不在美国生产iPhone,就要对其征收至少25%的关税。随后不久,特朗普又再度升级了他的“关税威胁”,并称这条规则也同样适用于三星和其他智能手机制造商。 自上 ...
- breeze0316
- 4 小时前
- 支持
- 反对
- 收藏
-
特朗普再发关税威胁! 当地时间5月23日,特朗普针对苹果公司和欧盟的关税表态,令苹果公司股价、欧洲主要股票市场以及美股均出现大幅波动。 特朗普对关税连续表态全球金融市场巨震 5月23日,美国总统特 ...
- albel921
- 6 小时前
- 支持
- 反对
- 收藏